Prospective Grant of Exclusive License: Diagnostics of Fungal Infections; Correction, 38689 [05-13132]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 127 / Tuesday, July 5, 2005 / Notices
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: June 28, 2005.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–13131 Filed 7–1–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Prospective Grant of Exclusive
License: Diagnostics of Fungal
Infections; Correction
In the notice document appearing on
page 33905 in the Federal Register
issued on Friday, June 10, 2005, Vol. 70,
No. 111, make the following correction:
On page 33905 under Centers for
Disease Control and Prevention, change
the title ‘‘Prospective Grant of Exclusive
License: Diagnostics of Fungal
Infections’’ to ‘‘Prospective Grant of
Exclusive License: System and Methods
for Aerosolized Delivery of Vaccines’’
(remove previous title ‘‘Diagnostics of
Fungal Infections’’).
All other information in the document
remains unchanged.
Dated: June 24, 2005.
James D. Seligman,
Associate Director for Program Services,
Centers for Disease Control and Prevention.
[FR Doc. 05–13132 Filed 7–1–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Cellular, Tissue and Gene Therapies
Advisory Committee (formerly
Biological Response Modifiers
Advisory Committee); Notice of
Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Cellular, Tissue
and Gene Therapies Advisory
Committee.
General Function of the Committee:
To provide advice and
VerDate jul<14>2003
18:41 Jul 01, 2005
Jkt 205001
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held, via teleconference, on July 29,
2005, from 12:30 p.m. to 2:30 p.m.
Location: National Institutes of
Health, Bldg. 29B, conference room C,
8800 Rockville Pike, Rockville, MD.
This meeting will be held by
teleconference. The public is welcome
to attend the meeting at the previously
mentioned location. A speakerphone
will be provided at the specified
location for public participation in the
meeting.
Contact Person: Gail Dapolito, Center
for Biologics Evaluation and Research,
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852,
301–827–0314, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), code
3014512389. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: In open session, the
committee will hear brief opening
remarks and allow time for public
participation and comments related to
individual FDA research programs
during the open public hearing. The
committee will not hear presentations or
discuss individual research programs in
the open session (see Closed Committee
Deliberations below).
Procedure: On July 29, 2005, from
12:30 p.m. to 1:30 p.m., the meeting is
open to the public. Interested persons
may present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person by July 21, 2005. Oral
presentations from the public will be
scheduled between approximately 12:30
p.m. to 1:30 p.m. Time allotted for each
presentation may be limited. Those
desiring to make formal oral
presentations should notify the contact
person before July 21, 2005, and submit
a brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation.
Closed Committee Deliberations: On
July 29, 2005, from approximately 1:30
p.m. to 2:30 p.m., the meeting will be
closed to permit discussion where
disclosure would constitute a clearly
unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). The
committee will discuss a review of
individual FDA research programs.
Persons attending FDA’s advisory
committee meetings are advised that the
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
38689
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Gail Dapolito
at least 7 days in advance of the
meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: June 23, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External
Relations.
[FR Doc. 05–13122 Filed 7–1–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004D–0333]
Draft Guidance; Emergency Use
Authorization of Medical Products;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of draft guidance entitled
‘‘Emergency Use Authorization of
Medical Products.’’ The draft guidance
explains FDA’s policies for authorizing
the use of an unapproved medical
product or an unapproved use of an
approved medical product during a
declared emergency. The draft guidance
is not final and is not in effect at this
time. FDA also is announcing an
opportunity for public comment on the
proposed collection of information
related to emergency use authorizations
by the agency.
DATES: Submit written or electronic
comments on the draft guidance and the
proposed collection of information by
September 6, 2005.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Office of Counterterrorism Policy and
Planning (HF–29), Food and Drug
Administration, 5600 Fishers Lane, rm.
14C–26, Rockville, MD 20857. Send a
self-addressed adhesive label to assist
that office in processing your request, or
fax your request to 301–827–5671.
Submit written comments on the draft
guidance and the proposed collection of
information to the Division of Dockets
E:\FR\FM\05JYN1.SGM
05JYN1
]]>Agencies
[Federal Register Volume 70, Number 127 (Tuesday, July 5, 2005)]
[Notices]
[Page 38689]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-13132]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Prospective Grant of Exclusive License: Diagnostics of Fungal
Infections; Correction
In the notice document appearing on page 33905 in the Federal
Register issued on Friday, June 10, 2005, Vol. 70, No. 111, make the
following correction:
On page 33905 under Centers for Disease Control and Prevention,
change the title ``Prospective Grant of Exclusive License: Diagnostics
of Fungal Infections'' to ``Prospective Grant of Exclusive License:
System and Methods for Aerosolized Delivery of Vaccines'' (remove
previous title ``Diagnostics of Fungal Infections'').
All other information in the document remains unchanged.
Dated: June 24, 2005.
James D. Seligman,
Associate Director for Program Services, Centers for Disease Control
and Prevention.
[FR Doc. 05-13132 Filed 7-1-05; 8:45 am]
BILLING CODE 4163-18-P
